Literature DB >> 10485455

Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line.

Y G Goan1, B Zhou, E Hu, S Mi, Y Yen.   

Abstract

In this study, human oropharyngeal epidermoid carcinoma KB cells that were resistant to 2,2-difluorodeoxycytidine (dFdCyd) were selected and designated the KB-Gem clone. The KB parental cell line IC50 was 0.3 microM dFdCyd, as compared with the KB-Gem clone IC50 of 32 microM dFdCyd. The KB-Gem clone demonstrated overexpression of ribonucleotide reductase (RR) M2 subunit mRNA (9-fold) and overexpression of M2 protein (2-fold); RR activity was 2.3-fold higher than the KB parental cell line. Both the dATP and dCTP pools of the KB-Gem clone increased 2-fold over the parental cell line, with no change in the dGTP and dTTP pools. Reverse transcriptase-PCR was used to clone the cDNA of deoxycytidine kinase (DCK). Resulting sequences revealed two silent mutations in the KB-Gem clone. The amino acid sequence of the DCK protein and mRNA expression remained unchanged. The KB-Gem clone's DCK enzyme activity was 56% of that of the parental cell line. After the endogenous dNTPs were removed with a G-25 column, no difference was evident between the enzyme activities of the KB-Gem clone and parental cells. Thus, contrary to previous hypotheses, DCK deficiency does not play the primary role in the resistance mechanism of dFdCyd, accepting a secondary role to the overexpression of the target gene, RR, and pool expansion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485455

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

1.  Optimization and evaluation of electroporation delivery of siRNA in the human leukemic CEM cell line.

Authors:  Anna Fyrberg; Kourosh Lotfi
Journal:  Cytotechnology       Date:  2010-10-19       Impact factor: 2.058

2.  Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.

Authors:  Nobuyuki Yoshio; Yasukazu Kawai; Hiroki Hori; Takanori Ueda
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

3.  False cell lines: The problem and a solution.

Authors:  John R Masters
Journal:  Cytotechnology       Date:  2002-07       Impact factor: 2.058

4.  Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.

Authors:  Soukaina Réjiba; Christelle Bigand; Céline Parmentier; Amor Hajri
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

5.  Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.

Authors:  Dharmika S P Lansakara-P; B Leticia Rodriguez; Zhengrong Cui
Journal:  Int J Pharm       Date:  2012-03-16       Impact factor: 5.875

6.  Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2.

Authors:  Aili Suo; Mingxin Zhang; Yu Yao; Lingmin Zhang; Chen Huang; Kejun Nan; Wanggang Zhang
Journal:  Med Oncol       Date:  2011-07-07       Impact factor: 3.064

Review 7.  DNA polymerase eta and chemotherapeutic agents.

Authors:  Kai-ming Chou
Journal:  Antioxid Redox Signal       Date:  2011-03-18       Impact factor: 8.401

8.  A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.

Authors:  Amir Mortazavi; Yonghua Ling; Ludmila Katherine Martin; Lai Wei; Mitch A Phelps; Zhongfa Liu; Erica J Harper; S Percy Ivy; Xin Wu; Bing-Sen Zhou; Xiyong Liu; Deidre Deam; J Paul Monk; William J Hicks; Yun Yen; Gregory A Otterson; Michael R Grever; Tanios Bekaii-Saab
Journal:  Invest New Drugs       Date:  2012-07-31       Impact factor: 3.850

9.  RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.

Authors:  Song Dong; Ai-Lin Guo; Zhi-Hong Chen; Zhen Wang; Xu-Chao Zhang; Ying Huang; Zhi Xie; Hong-Hong Yan; Hua Cheng; Yi-Long Wu
Journal:  J Hematol Oncol       Date:  2010-03-13       Impact factor: 17.388

10.  Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase.

Authors:  Glen Reid; Natacha Coppieters 't Wallant; Rachna Patel; Ana Antonic; Faamatala Saxon-Aliifaalogo; Helen Cao; Gill Webster; James D Watson
Journal:  J RNAi Gene Silencing       Date:  2009-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.